Panvel stock gains 3.23 percent on October 5

Published on 10/05/2026 at 12:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Panvel stock was quoted at BRL 13.12 on October 5, 2026, while BTG Pactual kept a BRL 19.00 target. Its 2026 revenue forecast is BRL 6.334 billion.

Panvel, BRPNVLACNOR9, Illustration mit AI erstellt.

Panvel (BRPNVLACNOR9) was quoted at BRL 13.12 on B3 on October 5, 2026, up 3.23 percent. The market value comes as BTG Pactual maintains a BRL 19.00 price target after Panvel's second-quarter 2026 results exceeded the bank's estimates.

BTG keeps BRL 19 target

According to BTG Pactual on September 22, 2026, the bank kept its target at BRL 19.00 for the end of 2027 and raised its projected net income by 11 percent. Against the October 5 quote of BRL 13.12, that target lies 44.8 percent above the price.

The research links the revised estimates to stronger operating execution, digital penetration, expansion prospects and rising demand for GLP-1 medicines. It also identifies competition, the macroeconomic backdrop and regulation as key risks for the investment case.

Revenue forecast reaches BRL 6.334 billion

BTG Pactual projects Panvel's 2026 net revenue at BRL 6.334 billion, compared with BRL 5.512 billion in 2025. Its adjusted net income forecast is BRL 185 million for 2026 and BRL 238 million for 2027, while projected EBITDA reaches BRL 400 million in 2026.

The bank forecasts a 5.9 percent EBITDA margin for 2026, 50 basis points above the prior year. That remains below Panvel's long-term guidance range of 6.7 percent to 7 percent, making margin delivery a central test of the expansion story.

GLP-1 sales reshape the mix

For the first half of 2026, BTG Pactual estimates that Panvel's net GLP-1 revenue grew 91 percent. The category represented 11.3 percent of sales in the second quarter, or BRL 184 million, and the bank expects its share to reach 12.4 percent in the fourth quarter.

The growth opportunity comes with a margin tradeoff because GLP-1 products currently carry a less favorable mix. Panvel's ability to offset that pressure through selling, general and administrative cost dilution will determine whether the revenue increase converts into sustained earnings growth.

Panvel stock holds a midrange valuation

Panvel's B3 quote of BRL 13.12 on October 5, 2026, sits between the 52-week low of BRL 9.01 and high of BRL 16.57. The same market page lists a market capitalization of BRL 2.0 billion, placing the share price 20.8 percent below its 52-week high.